Thank you, Rajiv, and thank you, everyone, for joining us. I will first discuss our Q4 fiscal 2024 and full fiscal year 2024 results, followed by our guidance for Q1 fiscal 2025 and for the full fiscal year 2025. Results in Q4 2024 came in above the high end of our range across all guided metrics. ACV billings in Q4 were $338 million, above the guided range of $295 million to $305 million, representing year-over-year growth of 21%. Revenue in Q4 was $548 million, higher than the guided range of $530 million to $540 million, representing a year-over-year growth of 11%. ARR at the end of Q4 was $1.908 billion, representing year-over-year growth of 22%. In Q4, we continue to see modestly elongated average sales cycles compared to historical levels. Average contract duration in Q4 was 3.1 years, 0.1 year higher than Q3. Non-GAAP gross margin in Q4 was 86.9%, higher than our guided range of 85% to 86%. Non-GAAP operating margin in to was 12.9% higher than our guided range of 9% to 10%, largely due to one, lower operating expenses as a result of higher-than-expected non-recurring payments related to one of our partnership agreements and a few other items; and two, slightly higher gross margin and revenue. Non-GAAP net income in Q4 was $76 million or fully diluted EPS of $0.27 per share based on fully diluted weighted average shares outstanding of approximately 285 million shares. DSOs based on revenue and ending accounts receivable were 39 days in Q4. Free cash flow in Q4 was $224 million, representing free cash flow margin of 41%. Free cash flow in Q4 benefited from the collection on the 8-figure ACV transaction that was booked in fiscal Q3. Moving to the balance sheet. We ended Q4 with cash, cash equivalence and short-term investments of $994 million, down from $1.651 billion at the end of Q3. The primary reason for the reduction in our cash balance was Bain Capital's conversion of the 2026 notes, which we announced in June. We settled the conversion in Q4 by paying $817.6 million in cash and delivering approximately 16.9 million shares of common stock. Please note that the entire conversion value had previously already been included in our fully diluted weighted average share count on an if-converted basis. The actual settlement included a portion settled in cash rather than exclusively in shares, resulting in the issuance of approximately 17 million shares, which is 12 million lower than the 29 million that we had previously included on an if-converted basis. Moving to capital allocation. We repurchased about $25 million worth of shares in Q4 and $131 million worth of shares in all of fiscal year 2024 under the share repurchase program previously authorized by our Board of Directors. Looking at our full year financial results, we exceeded the high end of all guided metrics for fiscal year 2024. ACV billings in fiscal year 2024 were $1.162 billion, higher than our guidance of $1.12 billion to $1.13 billion, and representing a year-over-year growth of 21%. A reminder that the annual ACV billings is slightly lower than the sum of the ACV billings from the four quarters due to adjustments for deals with duration of less than a year. Revenue in fiscal year 2024 was $2.149 billion, higher than our guidance of $2.13 billion to $2.14 billion and representing a year-over-year growth of 15%. We are pleased to have exceeded the $2 billion revenue threshold in fiscal year 2024. We ended fiscal year 2024 with an ARR of $1.908 billion, as mentioned earlier, a year-over-year growth of 22%. Net dollar-based retention rate, or NRR, at the end of fiscal year 2024 was 114%. As the fiscal year progressed, we saw a higher mix larger deals in our pipeline. These larger opportunities often involve strategic decisions and C-suite approvals causing them to take longer to close and to have greater variability in timing, outcome and deal structure. And as we mentioned previously, we have continued to see a modest elongation of average sales cycles relative to historical levels. Largely due to these dynamics, our fiscal year 2024 land and expand ACV and ARR performance were below our initial expectations at the beginning of the fiscal year, and we expect these dynamics to continue. Our renewals performance continues to be good through the fiscal year, and a reminder that renewals tend to be at a lower aggregate average contract duration compared to land and expand. Average contract duration in fiscal year 2024 was 2.95 years, flattish to fiscal year 2023 and slightly higher than expected, partly due to some larger deals with greater than average duration. Non-GAAP gross margin in fiscal year 2024 was 86.7%. Non-GAAP operating expenses in fiscal year 2024 were $1.515 billion, an increase of 7% year-over-year, as we began to make additional investments primarily in research and development and sales and marketing. Non-GAAP operating margin in fiscal year 2024 was 16%, representing an improvement of over 700 basis points year-over-year. We also delivered our first full year of positive GAAP operating income of $8 million in fiscal year 2024. Non-GAAP net income was $384 million, or diluted EPS of $1.31 per share based on fully diluted weighted average shares outstanding of approximately 294 million shares. Free cash flow in fiscal year 2024 was $598 million, higher than our guidance of $520 million to $540 million and almost 3 times higher than last year's free cash flow. Free cash flow margin in fiscal year 2024 was 28%, implying free cash flow margin expansion of 17 percentage points year-over-year. Free cash flow in fiscal year 2024 benefited from approximately $30 million in nonrecurring payments related to a partnership agreement, as previously referenced. Overall, fiscal year 2024 was a significant year, marking our first year with positive GAAP operating income, significant free cash flow generation of $598 million and free cash flow margin of 28%, while growing ARR at 22% and revenue at 15% year-over-year. We also delivered a Rule of 40 score defined as the sum of revenue growth and free cash flow margin of 43 for fiscal year 2024, an improvement of 14 percentage points year-over-year and 28 percentage points higher compared to two years ago. Moving to fiscal year 2025. The guidance for the full year is as follows; revenue of $2.435 billion to $2.465 billion, representing a year-over-year growth of 14% at the midpoint; non-GAAP operating margin of approximately 15.5% to 17%; free cash flow of $540 million to $600 million, representing a free cash flow margin of approximately 23% at the midpoint. I will now provide some commentary regarding our fiscal year 2025 guidance. First, as previously mentioned at our 2023 Investor Day, we are signing our metrics by not reporting or guiding ACV billings starting in fiscal year 2025. ACV billings was intended as a transitional metric during our subscription evolution, and we believe that now is the time to evolve away from that metric. We are also no longer guiding to GAAP gross margin which was previously useful as we navigated our business model changes, leading to significant improvements in non-GAAP gross margin. We will continue to guide to revenue, non-GAAP operating margin, and free cash flow on an annual basis and to guide to revenue and non-GAAP operating margin for the subsequent quarter. Second, and moving on to assumptions in our guidance, we are seeing continued and significant land-an-d expand opportunities and a growing pipeline for our solution. However, we continue to see a higher mix of larger deals in our pipeline, which is driving greater variability in our land and expand bookings. These larger opportunities often involve strategic decisions and C-suite approvals at the customer or prospect, causing them to take longer to close and to have greater variability in timing, outcome, and deal structure. And as we mentioned previously, we have continued to see a modest elongation of average sales cycles relative to historical levels, which we expect to continue. Third. The guidance assumes that renewals will continue to perform well in fiscal year 2025. Fourth. The full year guidance assume that average contract duration would be flat to slightly lower compared to fiscal year 2024, as renewals continue to grow as a percentage of our billing. Fifth. The non-GAAP operating margin guidance assumes incremental student investments in sales and marketing and R&D targeted towards addressing our large market opportunity. It also factors in the annualized run rate of the incremental investments we made in fiscal year 2024. It also assumes a $20 million to $25 million headwind in operating expenses relative to fiscal year 2024 from payments related one of our partnership agreement. Specifically, there was about $44 million of this benefit to the R&D operating expense line in fiscal year 2024, and we anticipate it be $20 million to $25 million in fiscal year 2025 And sixth. The free cash flow guidance reflects an approximately $30 million headwind relative to fiscal year 2024, from lower interest income as a result of our lower invested cash due to the cash payment on conversion of FY 2026 convertible notes. We expect free cash flow in fiscal year 2025 to also benefit from the approximately $30 million in nonrecurring payments related to a partnership agreement, similar to the benefit we saw in fiscal year 2024. It is expected to tail off towards the end of fiscal year 2025. Moving to Q1 2025. Our guidance for Q1 is as follows; revenue of $565 million to $575 million, non-GAAP operating margin of 14.5% to 15.5%. Fully diluted weighted average shares outstanding of approximately 287 million shares. In closing, we are pleased that Q4 and fiscal year 2024 performance exceeded guidance across all metrics. We are excited about the long-term market opportunity and Nutanix's ability to deliver compelling outcomes for customers and prospects. We remain committed to continued progress aligned with our stated philosophy of sustainable, profitable growth both through durable top line growth and expanding margins. With that, operator, please open the line for questions.